Hilton Hotels Corporation Common Stock vs Novartis AG — how do they compare? Hilton Hotels Corporation Common Stock trades at $320.63 (market cap $70.82B), while Novartis AG trades at $152.93 (market cap $295.37B). The key difference: Novartis AG is far larger — about 4.2× Hilton Hotels Corporation Common Stock's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| HLT | NVS | |
|---|---|---|
Market Cap | $70.82B | $295.37B |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $168.62 |
52-Week Low | $256.75 | $119.31 |
Enterprise Value | $83.83B | $336.69B |
Dividend Yield | 0.19% | 3.07% |
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide Holdings (HLT) trades at $311.00, down 2.08% over 24 hours, amid a bearish technical signal. The stock shows strong fundamentals with Q2 2026 EPS of $2.29 meeting estimates and revenue growth to $12.04 billion in 2025. However, a high P/E of 46.21 and rising debt-to-asset ratio to 73.88% in 2025 highlight valuation and leverage concerns. Recent news includes a 50-day strike at a Seattle hotel and mixed institutional trading activity.
The outlook for HLT is cautiously optimistic, supported by robust travel demand and a record pipeline, but tempered by premium valuation and debt risks. Analysts maintain a buy consensus with a $352.00 price target, suggesting 13% upside. Key risks include labor disputes, soft international demand, and interest rate sensitivity. Investors should weigh growth prospects against financial leverage and market sentiment shifts.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Trailing returns across standard periods
Latest headlines on both assets
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →